Envafolimab vs HLX43

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline

Envafolimab

Marketed by Suzhou Alphamab and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT05068427 · Phase 2 · completed

The study was an open-label, single-arm trial of 34 patients receiving chidamide plus envafolimab, with no randomized control group for comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT05024214 (registry estimate)

Reported efficacy

objective response rate (ORR) (Response is assessed once every 8 weeks, assessed up to 24 weeks.): Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months (not_applicable)

Result source: NCT05068427

HLX43

Developed by Shanghai Henlius Biotech

Phase 2/3 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07253142 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnvafolimabHLX43
PFS, median—Trial running · NCT06123754—Trial running · NCT07459751
OS, median—Trial running · NCT06123754—Trial running · NCT07459751
ORR—Trial running · NCT06123754—Trial running · NCT07459751
Duration of response, median—Trial running · NCT06123754—Trial running · NCT07459751

PFS, median

Envafolimab
—Trial running · NCT06123754
HLX43
—Trial running · NCT07459751

OS, median

Envafolimab
—Trial running · NCT06123754
HLX43
—Trial running · NCT07459751

ORR

Envafolimab
—Trial running · NCT06123754
HLX43
—Trial running · NCT07459751

Duration of response, median

Envafolimab
—Trial running · NCT06123754
HLX43
—Trial running · NCT07459751
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HLX43: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Envafolimab
Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months NCT05068427 · Phase 2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envafolimab's landscape · HLX43's landscape